Harvard Management Company’s Nurix Therapeutics NRIX Stock Holding History

Harvard Management Company’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-314,762	Closed	-$3.14M	–	27
2023 Q2	$3.14M	Hold	314,762	–	–	0.31%	16
2023 Q1	$2.8M	Hold	314,762	–	–	0.29%	29
2022 Q4	$3.46M	Hold	314,762	–	–	0.43%	27
2022 Q3	$4.1M	Hold	314,762	–	–	0.51%	25
2022 Q2	$3.99M	Hold	314,762	–	–	0.46%	25
2022 Q1	$4.41M	Hold	314,762	–	–	0.45%	30
2021 Q4	$9.11M	Hold	314,762	–	–	0.86%	20
2021 Q3	$9.43M	Hold	314,762	–	–	0.55%	25
2021 Q2	$8.35M	Hold	314,762	–	–	0.48%	25
2021 Q1	$9.79M	Hold	314,762	–	–	0.55%	24
2020 Q4	$10.3M	Hold	314,762	–	–	0.56%	17
2020 Q3	$11M	Buy	+314,762	New	+$7.93M	0.6%	16

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harvard Management Company's NRIX Position: Q3 2023 in Review

Harvard Management Company sold out of Nurix Therapeutics (NRIX) in Q3 2023, closing a stake of 314,762 shares — an estimated $3.14M sold.

Harvard Management Company first reported a position in NRIX in Q3 2020 and held it in 12 quarters. The position peaked at $11M in Q3 2020. 128 funds tracked by Wall St. Rank hold NRIX as of Q3 2023.

Harvard Management Company reported no remaining Nurix Therapeutics position as of Q3 2023 after selling out during the quarter.
Harvard Management Company sold 314,762 Nurix Therapeutics shares in Q3 2023, an estimated $3.14M.
Harvard Management Company first reported a position in Nurix Therapeutics in Q3 2020 and held it in 12 quarters.
Harvard Management Company's Nurix Therapeutics position peaked at $11M in Q3 2020.
128 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2023.

Based on Harvard Management Company's 13F filing for Q3 2023, filed 9 Nov 2023.